glp 1 agonists vs sglt2 inhibitors Recommendations for SGLT2i versus GLP-1 RA on the basis of kidney SGLT2 vs GLP-1 for CKD:

The Trump administration announced initiatives in November 2025 to expand GLP-1 access for Medicare beneficiaries with obesity plus significant comorbidities, with implementation expected around mid-2026

10.1039/d4fo01059k 102 TolhurstG.HeffronH.LamY

Perez-Garcia A, Hurtado-Carneiro V, Herrero-De-Dios C, Dongil P, Garcia-Maurino JE, Sanchez MD, et al

Importantly, the triagonist also lowered fasting blood glucose levels and improved glucose tolerance without inducing hypoglycemia

Consuming drugs or alcohol, and participating in any activity that is pleasurable or rewarding will temporarily increase dopamine firing above baseline in the reward pathway, making this area of the brain a good target for medications to treat addiction